Funding round completed
Reproductive medicine specialist PregLem SA has announced the closing of a CHF 32 million (€19 million) first-round funding led by Sofinnova Partners, with NeoMed Management and MVM Life Science Partners LLP.
At the same time the company said it signed a licensing agreement with the French pharmaceuticals group Ipsen SA, granting PregLem worldwide development and commercialisation rights on certain Ipsen compounds, for use in reproductive medicine only. The details of the agreement are not being disclosed.
The funding will allow PregLem to undertake the development of these and other. Sutrepa, an affiliate of Ipsen, has taken a minority equity stake in the company
PregLem was founded in Geneva in 2006, by Ernest Loumaye MD, a specialist in reproductive medicine, with 15 years’ experience in the biopharmaceutical industry, and by Eric Rolin, a finance executive with 25 years’ experience in the pharmaceutical industry.
The company said it is seeking further partnerships and in-licensing opportunities.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.